Precision Biosciences (DTIL) Current Deferred Revenue (2018 - 2025)

Precision Biosciences (DTIL) has 8 years of Current Deferred Revenue data on file, last reported at $6.2 million in Q3 2025.

• On a quarterly basis, Current Deferred Revenue rose 3470.29% year-over-year to $6.2 million in Q3 2025; TTM through Sep 2025 was $6.2 million, a 3470.29% increase from a year earlier, with the FY2024 full-year figure at $3.0 million, down 75.43% from the prior year.
• Current Deferred Revenue for Q3 2025 stood at $6.2 million, up from $6.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for DTIL reached as high as $53.1 million in Q1 2021 and fell as low as $175000.0 in Q3 2024.
• Historically, Current Deferred Revenue has averaged $20.5 million across 5 years, with a median of $19.7 million in 2022.
• Across the five-year window, Current Deferred Revenue plunged 99.0% in 2024 and surged 3470.29% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $21.2 million in 2021, then surged by 117.44% to $46.2 million in 2022, then tumbled by 73.95% to $12.0 million in 2023, then plunged by 75.43% to $3.0 million in 2024, then soared by 111.3% to $6.2 million in 2025.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $6.2 million in Q3 2025, $6.0 million in Q2 2025, and $5.7 million in Q1 2025.